# Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

> **NCT00828204** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 95 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DEVICE:** single-use autoinjector with a prefilled liquid Avonex syringe
- **DEVICE:** Avonex prefilled syringe via manual IM injection
- **DRUG:** BG9418 (interferon beta-1a)

## Key facts

- **NCT ID:** NCT00828204
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-07
- **Final completion:** 2010-10
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2014-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00828204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00828204, "Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00828204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*